Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.
Debdulal ChakrabortyMichael W StewartJay U ShethTushar K SinhaSubhendu BoralArnab DasSoumen MondalAngshuman MukherjeePublished in: Ophthalmology and therapy (2021)
The study reports the largest pooled safety data on IVRz use in a real-world scenario. The results did not raise any new ocular or systemic safety concerns for the biosimilar agent, with the incidence and spectrum of adverse reactions similar to those reported with other anti-vascular endothelial growth factor (anti-VEGF) drugs. The real-world evidence suggests that IVRz is a safe anti-VEGF agent in the management of chorioretinal disorders.
Keyphrases
- vascular endothelial growth factor
- endothelial cells
- diabetic retinopathy
- clinical trial
- electronic health record
- machine learning
- adipose tissue
- randomized controlled trial
- skeletal muscle
- weight loss
- insulin resistance
- drug induced
- big data
- artificial intelligence
- deep learning
- optical coherence tomography
- open label